WaveMan
WaveMan · Company
MPLT · Maplight Therapeutics, Inc.
> Search tickers & screens ⌘K
LIVE
← All companies

MPLT MapLight Therapeutics (MPLT) Insider Trading, Ownership & Congress Trades

Pharma & Biotech · Pharmaceutical preparations · CIK 0001770069
Quote by TradingView
Form 144 · 10
House members buying, 1 year
0
STOCK Act, US House only, disclosed up to 45 days after the trade
Funds added, last quarter
57
13F, latest reported quarter

What the filings say about MPLT

Insiders, 180 days
-$24.0M net sold
1 buyer · 7 sellers · 1% of sales under a 10b5-1 plan
Planned sales (Form 144), 90 days
$25.7M
10 notices

MapLight Therapeutics insider trades (Form 4)

Form 4 buys and sells (codes P and S). Grants, option exercises and conversions excluded.

Over the last 180 days, MapLight Therapeutics, Inc. insiders sold a net $24.0M of stock across 151 Form 4 purchases and sales, with 1 insider buying. Source: SEC Form 4 filings, as of 2026-10-28.

Insider
Filed
Shares
Value
Since filing
Kreitzer Anatol
Chief Discovery Officer
SELL
2026-10-16 SECtraded 2026-10-15
12,248
$96.0K
-4.3%
Context
  • 11 earlier Form 4 trades (code P or S) here by this insider (11 sales), the last on Jul 17, 2026.
  • The trade is 7.3% of the 168,678 shares held after it.
  • 5 other insiders sold within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Discovery Officer Kreitzer Anatol sold about $96.0K of MPLT on Oct 15, 2026; 5 other insiders sold within 30 days and 57 funds added in the latest 13F quarter.
GILLIS JONATHAN
CAO and Interim CFO
SELL
2026-10-16 SECtraded 2026-10-15
10,167
$82.1K
-4.3%
Context
  • 13 earlier Form 4 trades (code P or S) here by this insider (13 sales), the last on Jul 17, 2026.
  • The trade is 7.1% of the 142,315 shares held after it.
  • 5 other insiders sold within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: CAO and Interim CFO GILLIS JONATHAN sold about $82.1K of MPLT on Oct 15, 2026; 5 other insiders sold within 30 days and 57 funds added in the latest 13F quarter.
Lillie James Woodruff
Chief Scientific Officer
SELL
2026-10-16 SECtraded 2026-10-15
11,513
$93.0K
-4.3%
Context
  • 20 earlier Form 4 trades (code P or S) here by this insider (20 sales), the last on Aug 3, 2026.
  • The trade is 5.8% of the 198,597 shares held after it.
  • 5 other insiders sold within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Scientific Officer Lillie James Woodruff sold about $93.0K of MPLT on Oct 15, 2026; 5 other insiders sold within 30 days and 57 funds added in the latest 13F quarter.
Hanson Kristopher
General Counsel
SELL
2026-10-16 SECtraded 2026-10-15
9,020
$72.9K
-4.3%
Context
  • 19 earlier Form 4 trades (code P or S) here by this insider (19 sales), the last on Sep 16, 2026.
  • The trade is 7.0% of the 128,024 shares held after it.
  • 5 other insiders sold within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: General Counsel Hanson Kristopher sold about $72.9K of MPLT on Oct 15, 2026; 5 other insiders sold within 30 days and 57 funds added in the latest 13F quarter.
Foff Erin Pennock
Chief Medical Officer
SELL
2026-10-16 SECtraded 2026-10-15
15,355
$124.1K
-4.3%
Context
  • 22 earlier Form 4 trades (code P or S) here by this insider (22 sales), the last on Jul 17, 2026.
  • The trade is 5.2% of the 296,906 shares held after it.
  • 5 other insiders sold within 30 days.
  • 57 funds added in the 13F quarter to Jun 30, 2026.
Insider activity: Chief Medical Officer Foff Erin Pennock sold about $124.1K of MPLT on Oct 15, 2026; 5 other insiders sold within 30 days and 57 funds added in the latest 13F quarter.
151 transactions on record
Since filing: total return from the first close after the filing to the latest close, dividend-adjusted. Not a forecast.
Context lines are counts over the filings above and returns from our own price history, never a price level. Not investment advice.
See all insider buying · insider selling
Showing the latest few. to see 146 more transactions and use the screener and CSV export. We store only your email; there is no password.
Seven facts, ranked against the sector · Rank is not a forecast
Insiders
net -$24.0M over 180 days
-$1.5M over 90 days
below 89% of Pharma & Biotech
Congress
no House purchase disclosed in the last 12 months
Funds
57 funds bought in last quarter
more than 50% of Pharma & Biotech
Revenue
no revenue reported in any filing
Margin
no margin: no revenue reported
Buybacks
no share repurchases reported
Short interest
21.0% of the float short (float per yahoo 2026-10-27) · 8.3 days to cover · settled 2026-10-15
more than 64% of Pharma & Biotech
What changed in the last 30 days
Oct 16Chief Executive Officer Kroeger Christopher A. sold $595.4K (Oct 15)
Oct 16Chief Medical Officer Foff Erin Pennock sold $124.1K (Oct 15)
Oct 15Officer Kroeger Christopher A. filed to sell $575.5K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 15Officer Foff Erin Pennock filed to sell $119.9K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.
Oct 15Director ROBERT MALENKA filed to sell $115.7K by Oct 15 (Form 144)
Why it matters
A Form 144 is a notice of intent to sell; the sale may not happen, and it says nothing about the price.

Watch MPLT

A free account keeps a watchlist and can send one email a day when insiders, funds or Congress file on the names in it. No password and no card.

The year, with the filings on it
Total return over 12 months. Each marker is a filing; hover or tap one for the detail.
-58.2%12M
-58%+0%+59%+117%2025-102025-122026-022026-042026-062026-082026-10 2025-10-28 · Novo Holdings A/S bought $16.2M2026-05-18 · Kroeger Christopher A. sold $3.2M2026-07-15 · Kroeger Christopher A. sold $1.6M2026-07-16 · Kroeger Christopher A. sold $1.5M2026-07-16 · Kroeger Christopher A. sold $1.0M2026-04-27 · GILLIS JONATHAN sold $876.8K2026-04-27 · Kreitzer Anatol sold $866.8K2026-05-08 · Kroeger Christopher A. sold $814.1K2026-07-15 · Kroeger Christopher A. sold $682.2K2026-07-17 · GILLIS JONATHAN sold $638.2K2026-07-17 · Kroeger Christopher A. sold $635.9K2026-10-15 · Kroeger Christopher A. sold $595.4K2026-07-17 · Kreitzer Anatol sold $533.1K2026-04-28 · GILLIS JONATHAN sold $522.7K2026-05-06 · Lillie James Woodruff sold $478.3K2026-05-06 · Foff Erin Pennock sold $463.2K2026-05-06 · Kroeger Christopher A. sold $454.5K2026-04-27 · GILLIS JONATHAN sold $437.5K2026-05-07 · Kroeger Christopher A. sold $423.6K2026-01-29 · Malenka Robert C. sold $394.4K2026-07-16 · Foff Erin Pennock sold $334.1K2026-07-15 · Foff Erin Pennock sold $331.9K2026-07-15 · Foff Erin Pennock sold $290.6K2026-05-05 · Lillie James Woodruff sold $284.9K2026-05-05 · Setia Vishwas sold $279.4K2026-08-03 · Lillie James Woodruff sold $276.9K2026-07-16 · Kreitzer Anatol sold $273.6K2026-05-05 · Foff Erin Pennock sold $271.2K2026-05-05 · Kroeger Christopher A. sold $268.4K2026-07-15 · Foff Erin Pennock sold $258.7K2026-07-16 · GILLIS JONATHAN sold $255.9K2026-05-04 · Lillie James Woodruff sold $254.4K2026-05-04 · Setia Vishwas sold $254.2K2026-02-10 · Garnett Timothy John bought $252.7K2026-05-04 · Foff Erin Pennock sold $252.4K2026-05-04 · Kroeger Christopher A. sold $251.2K2026-05-04 · Hanson Kristopher sold $248.3K2026-04-15 · Kroeger Christopher A. sold $246.0K2026-04-27 · Kreitzer Anatol sold $241.7K2026-04-27 · Kreitzer Anatol sold $238.5K2026-05-06 · Setia Vishwas sold $238.2K2026-05-06 · Lillie James Woodruff sold $235.3K2026-10-15 · Foff Erin Pennock filed to sell $119.9K2026-10-15 · GILLIS JONATHAN filed to sell $79.4K2026-10-15 · Hanson Kristopher filed to sell $70.4K2026-10-15 · Anatol Kreitzer filed to sell $97.6K2026-10-15 · Kroeger Christopher A. filed to sell $575.5K2026-10-15 · Lillie James Woodruff filed to sell $89.9K2026-10-15 · ROBERT MALENKA filed to sell $115.7K2026-09-16 · Hanson Kristopher filed to sell $199.4K2026-08-03 · Lillie James Woodruff filed to sell $287.5K2026-07-30 · Novo Holdings A/S filed to sell $24.0M2026-07-17 · JONATHAN GILLIS filed to sell $687.4K2026-07-17 · ANATOL KREITZER filed to sell $639.2K2026-07-15 · Foff Erin Pennock filed to sell $1.8M2026-07-15 · Jonathan Gillis filed to sell $1.4M2026-07-15 · Hanson Kristopher filed to sell $625.8K2026-07-15 · Anatol Kreitzer filed to sell $1.3M2026-07-15 · Kroeger Christopher A. filed to sell $5.8M2026-07-15 · Lillie James Woodruff filed to sell $714.0K2026-07-15 · ROBERT MALENKA filed to sell $664.8K
Insider buyInsider sellForm 144 (planned sale)
Indexed to 100, dividend-adjusted, not a price chart. When a name files heavily, the largest trades are drawn first.

Who owns MPLT: institutional holders (13F)

13F holdings, latest reported quarter
NOVO HOLDINGS A/S
3,686,622 sh
$132.1M
FCPM III SERVICES B.V.
3,226,400 sh
$115.6M
GOLDMAN SACHS GROUP INC
1,948,312 sh
$69.8M
BlackRock, Inc.
1,025,134 sh
$36.7M
Nan Fung Group Holdings Ltd
971,253 sh
$34.8M

Congress trades in MPLT

No Congress trades reported
No House member has disclosed a trade in this stock. See what Congress is buying.

Activist and 5% holders (13D/13G)

No 5%+ ownership filings
Nobody has filed for crossing 5%. That is a fact, not missing data.

MPLT planned insider sales (Form 144)

Notice of intent to sell, filed before any sale
Foff Erin Pennock
Filed 2026-10-15
$119.9K
GILLIS JONATHAN
Filed 2026-10-15
$79.4K
Hanson Kristopher
Filed 2026-10-15
$70.4K
Anatol Kreitzer
Filed 2026-10-15
$97.6K
Kroeger Christopher A.
Filed 2026-10-15
$575.5K

MPLT mutual fund holders (N-PORT)

Funds ranked by the share of their own portfolio in this stock (N-PORT).
Lazard US Small Cap Equity Select Portfolio
$343.7K position · as of 2026-06-30
0.9%
T. Rowe Price Health Care ETF
$91.1K position · as of 2026-06-30
0.4%
Small-Cap Value Fund
$1.3M position · as of 2026-06-30
0.4%
Virtus Biotech Clinical Trials Etf
$145.8K position · as of 2026-07-31
0.3%
T. Rowe Price Institutional Small-Cap Stock Fund
$12.3M position · as of 2026-06-30
0.2%
T. Rowe Price Small-Cap Stock Fund, Inc.
$22.4M position · as of 2026-06-30
0.2%
SEC N-PORT, monthly, about 60 days late · funds ≥ $10M · % is the share of the fund's own portfolio
Clinical pipeline
6 registered trials, 4 still running (ClinicalTrials.gov). A status change is dated here weeks before the press release.
6
Phase 2
4 active
Matched by sponsor name. Trials run under a subsidiary's own name are not included.
Live price
Daily candles from TradingView, under their licence. No filings marked.
Why this name is on the desk
Insiders have filed to sell, before selling.
The record shows a net $24.0M sold by insiders over 180 days, 57 funds added last quarter, $25.7M in planned Form 144 sales. Each figure is a federal filing, dated the day it went public.
Backtest this pattern Open the screener
Same sector, ranked by filing activity
Sector by SEC SIC code
UTHRCPIXMRNAREGNLLYALNYMDGLCITRDNAVRTXNUVLTWST

MPLT financials

Ratios from the company's XBRL filings, latest filings
Revenue, TTM
n/a
fewer than four consecutive quarters of revenue filed
Net margin, TTM
n/a
needs four consecutive quarters of both revenue and net income
Free cash flow, TTM
-$175.1M
operating cash flow minus capex, 2025-07-01 to 2026-06-30
Debt to equity
n/a
no debt line filed
Cash flow to debt
n/a
no debt line filed
Return on equity
-445.2%
TTM net income over average of 2025-06-30 and 2026-06-30
Return on assets
-62.4%
TTM net income over ending balance 2026-06-30
Return on invested capital
n/a
tax provision or pre-tax income not filed for the four quarters
Return on capital employed
-69.6%
operating income (EBIT proxy) over ending balance 2026-06-30 minus current liabilities
P/E, trailing
0.16x
close 2026-10-26 over four quarters of diluted EPS, 2025-07-01 to 2026-06-30
Enterprise value
n/a
no debt line filed
FCF yield
-53.9%
TTM free cash flow over market value at close 2026-10-26
PEG, trailing
n/a
prior-year trailing EPS was a loss, growth undefined
Price as of 2026-10-26. Hover or tap a tile for its yearly and quarterly history.
Method
TTM is four consecutive fiscal quarters; Q4 is the year minus nine months when not filed. Returns use the average of opening and closing balances. EBIT is approximated by operating income. PEG uses trailing EPS growth.
Fundamentals
Annual figures from XBRL filings. Pick a past date to see them as known then.
2025-122024-12
Operating income-$169.1M-$82.9M
Net income-$161.2M-$77.6M
EPS (diluted)-18.56-105.38
Operating cash flow-$138.1M-$78.8M
Cash$46.7M$38.3M
SEC XBRL, fiscal years, as known on 2026-10-28

MPLT Stock Sonar score 4/7 axes

Find similar shapesCompare

MPLT ranks highest on institutional and government (50th percentile) and insider conviction (32nd), and lowest on risk and compliance (14th), among Pharma & Biotech peers.

Profitability
27
Inputs
  • Return on equity-445.2% · 8 pct, sector of 545
  • Return on assets-62.4% · 37 pct, sector of 691
  • Return on invested capitaltax provision or pre-tax income not filed for the four quarters
  • Return on capital employed-69.6% · 36 pct, sector of 576
Insider conviction
32
Inputs
  • Net Form 4 buying (codes P and S), 180d-$23.8M · 9 pct, sector of 429
  • Insider buyers, 180d1 · 56 pct, sector of 438
Institutional and government
50
Inputs
  • Funds adding, latest quarter57 · 50 pct, sector of 698
  • Congress net buyers, 365dno Congress trades in 365 days
  • Federal contracts, 180dno federal contracts in 180 days
  • Lobbying spend, 4 quartersno lobbying filings in the last four quarters
Risk and compliance
14
Inputs
  • Short interest, % of float+21.0% · 14 pct, sector of 816
  • Recalls per $1B revenue, 3yrevenue under $50M or not filed, so a count cannot be scaled to size
  • EPA cases per $1B revenue, 5yrevenue under $50M or not filed, so a count cannot be scaled to size
  • New text in Risk Factors, latest 10-Kneeds two 10-Ks with a Risk Factors section (not 20-F filers or stubs)
3 not measured: Financial health, Growth, US patents
  • Financial health needs 1 of 2 inputs, 0 present: no debt line filed
  • Growth needs 1 of 2 inputs, 0 present: no backlog line filed, or no year-earlier backlog; no revenue for this year and the year before
  • US patents needs 1 of 2 inputs, 0 present: patent data not loaded yet

4 of 7 axes scored. Each is a percentile against sector peers (all companies when the sector is thin); higher is better. An unscored axis is unmeasured, not low. How it is scored

MPLT filings, in plain words

Are MapLight Therapeutics insiders buying or selling MPLT?

In the 180 days to 2026-10-28, MapLight Therapeutics insiders were net sellers, a net $24.0M: $148.7K of purchases and $24.2M of sales reported on Form 4, by 1 buyer and 7 sellers.

Are there planned insider sales of MPLT?

Yes. 10 Form 144 notices of planned insider sales were filed in the 90 days to 2026-10-28, covering $25.7M of stock; the latest, by Foff Erin Pennock, was filed 2026-10-15.

Read the full summary

In the 180 days to 2026-10-28, MapLight Therapeutics insiders were net sellers of MPLT, a net $24.0M across purchases and sales reported on Form 4 by 1 buyer and 7 sellers. Sales outweighed purchases more than tenfold by value. 1% of the 106 insider sales were made under a Rule 10b5-1 plan; the rest were not flagged as planned. Insiders filed 10 Form 144 notices of intent to sell in the 90 days to 2026-10-28, covering $25.7M of stock. Each figure is counted from SEC and House filings as of 2026-10-28, dated the day the filing was made public.

Explore insider trading and ownership data

Every company we track, ranked by each kind of filing
Insider buyingInsider sellingCongress stock tradesActivist 13D stakesForm 144 planned salesCEO pay vs performanceAll companies